文献速递前列腺癌

不良中危与高危前列腺癌男性仅前列腺放疗对比全盆腔放疗的生存结局

Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy.
PubMed 文献 · J Urol · 2022-01-27

基于美国国家癌症数据库2008—2015年不良中危或高危前列腺癌男性记录,比较前列腺外照射放疗联合或不联合全盆腔放疗的生存结局。全盆腔放疗在淋巴结受累风险≥10%或Gleason 9—10分患者中与总生存改善相关,全体人群仅呈改善趋势(HR 0.95,95%CI 0.90—1.006,P=0.055)。

要点

  • 淋巴结受累风险每增加1%,死亡风险增加1%(P<0.001)。
  • 全盆腔放疗在淋巴结受累风险≥10%者中与总生存改善相关(HR 0.93,95%CI 0.87—0.99,P=0.03)。
  • Gleason 9—10分者接受全盆腔放疗与总生存改善相关(HR 0.87,95%CI 0.78—0.98,P=0.02)。

核心结论

  • 淋巴结风险评分较高和Gleason分级较高的男性从全盆腔放疗中获益。
  • 结果与近期POP-RT随机试验互补,提示未行功能影像分期的更异质性人群也可从全盆腔放疗中获益。

研究设计与样本

  • 回顾美国国家癌症数据库2008—2015年诊断为不良中危或高危前列腺癌、接受前列腺外照射放疗(72—86.4 Gy)联合或不联合雄激素剥夺治疗的男性记录。
  • 接受全盆腔放疗者15,175例,未接受者13,549例。
  • 使用纪念斯隆凯特琳癌症中心列线图计算淋巴结受累风险,采用逆概率治疗加权平衡已测量混杂因素,并用多变量Cox回归生成总生存风险比。

主要发现

  • 53%的男性接受了全盆腔放疗。
  • 淋巴结受累风险每增加1%,死亡风险增加1%(P<0.001)。
  • 全盆腔放疗在全体不良中危和高危前列腺癌男性中仅呈总生存改善趋势(HR 0.95,95%CI 0.90—1.006,P=0.055)。
  • 全盆腔放疗在Gleason 9和10分疾病男性中与总生存改善相关(HR 0.87,95%CI 0.78—0.98,P=0.02)。
  • 全盆腔放疗在淋巴结受累风险≥10%男性中与总生存改善相关(HR 0.93,95%CI 0.87—0.99,P=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Men with unfavorable intermediate-risk (UIR-PCa) or high-risk prostate cancer (HR-PCa) are often treated with definitive external beam radiotherapy (EBRT) plus androgen deprivation therapy. Treatment is frequently intensified by electively treating the pelvic lymph nodes (LNs) with whole pelvis radiotherapy (WPRT), but practice patterns and the benefits of WPRT are not well defined. We hypothesized that men treated with WPRT would have improved overall survival (OS) relative to men treated with prostate-only radiotherapy. MATERIALS AND METHODS: National Cancer Database records of men diagnosed between 2008-2015 with UIR-PCa or HR-PCa and treated with prostate EBRT±androgen deprivation therapy (72-86.4 Gy) with (15,175) or without (13,549) WPRT were reviewed. Risk of LN involvement was calculated using the Memorial Sloan Kettering Cancer Center nomogram. Measured confounders were balanced with inverse probability of treatment weighting and OS hazard ratios (HRs) were generated using multivariable Cox regression. RESULTS: Of the men, 53% received WPRT. Every 1% increase in risk of LN involvement correlated with a 1% increase in risk of death (p <0.001). WPRT trended toward improved OS in all men with UIR-PCa and HR-PCa (HR: 0.95 [95% CI: 0.90-1.006], p=0.055). WPRT correlated with improved OS in men with Gleason 9 and 10 disease (HR: 0.87 [0.78-0.98], p=0.02) or risk of LN involvement ≥10% (HR: 0.93 [0.87-0.99], p=0.03). CONCLUSIONS: Men with higher LN risk scores and Gleason grade benefited from WPRT. These results complement the recent POP-RT randomized trial in mostly positron emission tomography/computerized tomography-staged patients, demonstrating that a more heterogeneous population of men staged without functional imaging benefits from WPRT.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Andruska N, Fischer-Valuck BW, Waters M, et al. Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy. J Urol. 2022. PMID: 35085038. doi:10.1097/JU.0000000000002455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。